

# Customized laser cornea remodeling: Theory and clinical practice



**MEACO 09**




A. John Kanellopoulos, MD  
Clinical Associate Professor New York University Medical  
School  
Director, Laservision.gr Institute, Athens, Greece  
[www.brilliantvision.com](http://www.brilliantvision.com)



[www.brilliantvision.com](http://www.brilliantvision.com)

# Define customised in 2008?

- Wavefront guided?
- Topography guided?
- Wavefront-optimised?
- Asphericity adjustment?
- Adjustment to pupil size?
- Adjustment to angle kappa?
- Customised flap (Intralase)?
- Customizing cornea biomechanics with cross-linking?




Same pt other eye RMSH improved from 1,2 to 0.36 (!) LCS improved from C3 to C7 (!)



# Wavefront guided results:

Kanellopoulos et al, AAO 2004, JRS  
May 2006



## Wavefront-guided Enhancements Using the WaveLight Excimer Laser in Symptomatic Eyes Previously Treated With LASIK

A. John Kanellopoulos, MD; Lawrence H. Pe, MD

### ABSTRACT

**PURPOSE:** To describe our clinical experience in wavefront-guided LASIK enhancements using the WaveLight ALLEGRETTO system (WaveLight Technologie AG, Erlangen, Germany) for symptomatic eyes previously treated with standard LASIK.

**METHODS:** Twenty-six eyes of 20 patients with residual myopia, hyperopia, or mixed astigmatism and/or night vision symptoms after primary standard LASIK were considered for wavefront-guided customized retreatment using the WaveLight ALLEGRETTO WAVE 200 Hz excimer laser system (model 106). Preoperative best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity, topography, with the ALLEGRETTO Topolyzer, wavefront analysis using the ALLEGRETTO WAVE Topography Analyzer, and contrast sensitivity were compared to postoperative (enhancement) measurements.

**RESULTS:** Twenty-two of the original 26 eyes underwent wavefront-guided enhancement; 4 were excluded because they did not meet wavefront-guided treatment inclusion guidelines of this study. Mean follow-up was 8 months (range, 6 to 13 months). All patients were within  $\pm 0.50$  diopters (manifest refraction) of intended postoperative refraction. The mean preoperative BSCVA improved from 20/25 to 20/18 postoperatively. All patients gained at least one line of BSCVA, and a maximum of three lines. There was no loss of BSCVA in any patient. The total amount of high order aberrations (RMSH) decreased from an average of 1.04 to 0.46  $\mu\text{m}$ . Patients also had a mean improvement in low contrast sensitivity of 53%.

**CONCLUSIONS:** Based on this small series, customized wavefront-guided enhancements using the WaveLight ALLEGRETTO system in patients who underwent previous LASIK appear to be safe and effective in correcting residual refractive error, reducing high order aberrations, and improving visual symptoms when reliable and reproducible measurements are achieved. *J Refract Surg.* 2006;22:xx-xx.

**S**everal wavefront-guided excimer laser platforms are available today, and some have been shown to provide good results in enhancement in patients with residual problems after refractive surgery.<sup>1,2</sup> This study is designed to evaluate the safety and efficacy of wavefront-guided LASIK enhancements using the ALLEGRETTO system (Wavefront analyzer and ALLEGRETTO WAVE 200Hz excimer laser; WaveLight Technologie AG, Erlangen, Germany) for symptomatic eyes after LASIK.

### PATIENTS AND METHODS

Twenty-six symptomatic eyes that underwent LASIK were evaluated for possible wavefront-guided enhancement with the WaveLight ALLEGRETTO system. Inclusion criteria were previous LASIK surgery with residual myopia, hyperopia, or mixed astigmatism with a refractive error within  $\pm 1.50$  diopters (D) (spherical equivalent). The diameter of the planned wavefront-guided laser treatment had to be  $\geq 6$  mm and  $\leq 7$  mm. The root-mean-square higher order aberration (RMSH) value had to be  $\geq 0.4$   $\mu\text{m}$  when measured by the ALLEGRETTO WAVE Analyzer at a 6.5-mm pupil diameter. Indications included: 1) small original optical zone, 2) decentered ablation, 3) irregular astigmatism, 4) night vision problems, and 5) under- and overcorrection. An additional criterion for study inclusion was our ability to obtain highly reproducible, higher aberration maps that had a diameter of at least 6 mm after the eye had been dilated with a single drop of tropi-

From the LaserVision.gr Eye Institute, Athens, Greece; Department of Ophthalmology, Mount Sinai Eye, Ear and Throat Hospital, New York, NY; and Department of Ophthalmology, New York University Medical School, New York, NY.

The authors have no financial or proprietary interests in the materials presented herein.

Presented at: American Academy of Ophthalmology Annual Meeting, October 23-28, 2004, New Orleans, La.

Correspondence: A. John Kanellopoulos, MD, LaserVision.gr Eye Institute, Pnyx Alkman, Mesogeion 2 & Vasilikou Sofias, Anaplyskios, 11527, Athens, Greece. Tel: 30 210 7472 777; Fax 30 210 7472 788; E-mail: laservision@iinet.gr

Received: July 18, 2004

Accepted: June 12, 2005

# Accommodation





Fig 10 Overall spherical aberration becomes more negative as the eye accommodates.


# Center of pupil change with dilation(mydriasis)

Donnenfeld E. J Refract Surg. 2004 Sep-Oct;20(5):S593-6.



If the wavefront is captured in dim light and referenced to the pupil center...  
**Accurate before surgery**

Your wavefront ablation will be applied to the wrong area.



Here, a **260 micron shift** in pupil center is seen!

# Topography-guided

JRS Sept/Oct 2005

## Topography-guided Custom Retreatments in 27 Symptomatic Eyes

A. John Kanellopoulos, MD

### ABSTRACT

**PURPOSE:** To evaluate the use of topography-guided ablations for refractive irregularities induced by previous surgery.

**METHODS:** This prospective, non-comparative trial comprised 27 symptomatic eyes with a history of LASIK for myopia that underwent topography-guided treatment with the ALLEGRETTO WAVE system. Pre- and postoperative refractive, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), corneal astigmatism (Q value), low contrast sensitivity, and patient's subjective assessment of improvement were measured.

**RESULTS:** Preoperative data were sphere  $-0.84 \pm 1.3$  D (diopters (D)), cylinder  $-1.55 \pm 0.78$  D, UCVA 20/49  $\pm 0.22$ , BSCVA 20/32  $\pm 0.15$ , and Q value  $1.46 \pm 0.79$ . Postoperative data at mean 6-month follow-up were: sphere  $-0.61 \pm 0.81$  D, cylinder  $-0.53 \pm 0.55$  D, UCVA 20/25  $\pm 0.21$  ( $P = .01$ ), BSCVA 20/21  $\pm 0.14$  ( $P = .001$ ), and Q value  $1.07 \pm 0.89$ . Contrast sensitivity scores improved by 70%. No loss of BSCVA occurred in any patient.

**CONCLUSIONS:** Topography-guided treatments may be effective in correcting the quality of vision. It should be viewed as a possible two-step procedure due to spherical adjustment that may change refraction unpredictably. (*J Refract Surg.* 2005;21:S513-S518.)

Approximately 5% to 25% of refractive procedure result with a less than satisfactory outcome post operatively.<sup>1-10</sup> Aside from residual refractive error or overcorrection, these patients frequently have some form of irregular astigmatism induced by small optical zones and/or decentered ablations. These types of refractive errors are difficult to correct with standard treatments because of their irregular nature and would benefit more from customized ablation.

Although the term "customized treatment" usually is used for wavefront-guided treatments, topography-guided ablation is also a form of customized ablation. However, instead of conforming treatment to the wavefront map, it uses the patient's topography height map as the basis for the treatment.<sup>11</sup>

We previously reported our experience in enhancing these cases with wavefront-guided treatments with the ALLEGRETTO WAVE platform (WaveLight Technologie AG, Erlangen, Germany) with satisfactory success.<sup>12</sup>

### PATIENTS AND METHODS

The study design is a non-comparative case series on 27 eyes (22 patients) that underwent topography-guided enhancement with the ALLEGRETTO WAVE platform (Table). No control group was used or gender matching was done. These were consecutive cases that were treated by a single surgeon (A.J.K.) in a refractive surgery center in Athens, Greece.

Patients with previous myopic or hyperopic laser surgery who were dissatisfied with their quality of vision and either had residual myopia, hyperopia, or mixed astigmatism were included in the study. The indications were: 1) small origina

*From the LaserVision.gr Eye Institute, Athens, Greece; the Department of Ophthalmology, Manhattan Eye, Ear and Throat Hospital, New York, NY and the Department of Ophthalmology, New York University Medical School, New York, NY.*


*The author has no financial interest in the materials presented herein.*

*Presented in part at the Sixth International Congress on Wavefront Sensing and Optimized Refractive Corrections, February 11-13, 2005; Athens, Greece*

*Correspondence: A. John Kanellopoulos, MD, LaserVision.gr Eye Institute, Messogeion 2 & Vasilissis Sofias Ave, Ampelokipoi, 11527, Athens, Greece. Tel: 30 210 7472 777; Fax: 30 210 7472 789; E-mail: laser@vision@internet.gr*

Enlarging myopic optical zone:

Initially -10, 505 $\mu$  LASIK: 4,5mm OZ, 125 $\mu$  flap M2  $\rightarrow$  plano  $\wedge$  BCVA 2 lines, but night halos  
Topo-guided Tx to enlarge OZ to 6mm and adjusting Q value to -1,46 Initially halos gone,




Refraction: -1.25!



# Post-trauma irregular astigmatism

Old K perf, s/p CE, IOL, s/p LASIK for +2.00 now -1,50 -250 160 irregular BCVA 20/40+  
Topo-guided, Q adjustment to -0.3

Postop: UCVA 20/30, BCVA 20/25




# Post-surgery irregular astigmatism


Complicated CE-Aphakia-Artisan IOL-in an old LASIK pt

P -350 90 BCVA 20/60

Postop +0.50-0.50 90 UCVA 20/25




# Re-centering OZ, smoothing irregularities (Loss of K sliver in recuts)




# Centering optical zone-hyperopia

Initially: +3.50 -3.00 180, post LASIK:+1.00-1.25 70 UCV  
20/40 BCVA 20/25 pTOPOG: plano -0.25 UCVA 20/20



# Enlarging optical zone-RK


10 year post-RK, Post-LASIK: +2,50 -1,50Cyl, debilitating night vision. P topo-guided -0.50 -0.50 marked improvement



# Enlarging optical zone-



## Hyperopia

S/p LASIK for +4.50, now +1.00 and night vision down C3, s/p topo-guided CS=C7



# Post-keratitis irregular astigmatism

Patient with old severe Cornea ulcer and paracentral flattening  
-3.50-2.00 irregular cyl UCVA 20/200 to 20/25  
BSCVA from 20/40- to 20/25



# Topo-guided with the Wavelight-platform (Kanellopoulos-JRS Sept05)

- 8 high quality topographies

Adjustment for:

1-sphere

2-Cylinder

3-Axis

4-Q value (asphericity)

Standard angle-kappa adjustment

## Topography-guided Custom Retreatments in 27 Symptomatic Eyes

A. John Kanellopoulos, MD

### ABSTRACT

**PURPOSE:** To evaluate the use of topography-guided ablations for refractive irregularities induced by previous surgery.

**METHODS:** This prospective, non-comparative trial comprised 27 symptomatic eyes with a history of LASIK for myopia that underwent topography-guided treatment with the ALLEGRETTO WAVE system. Pre- and postoperative refraction, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), corneal asphericity (Q value), low contrast sensitivity, and patient's subjective assessment of improvement were measured.

**RESULTS:** Preoperative data were sphere  $-0.84 \pm 1.37$  diopters (D), cylinder  $-1.55 \pm 0.78$  D, UCVA 20/49  $\pm 0.22$ , BSCVA 20/32  $\pm 0.15$ , and Q value  $1.46 \pm 0.79$ . Postoperative data at mean 6-month follow-up were: sphere  $-0.61 \pm 0.81$  D, cylinder  $-0.53 \pm 0.58$  D, UCVA 20/25  $\pm 0.21$  ( $P < .01$ ), BSCVA 20/21  $\pm 0.14$  ( $P < .001$ ), and Q value  $1.07 \pm 0.89$ . Contrast sensitivity scores improved by 70%. No loss of BSCVA occurred in any patient.

**CONCLUSIONS:** Topography-guided treatments may be effective in restoring the quality of vision. It should be viewed as a possible two-step procedure due to spherical adjustment that may change tolerance unexpectedly. [J Refract Surg. 2005;21:5515-5518.]

Approximately 5% to 25% of refractive procedure result with a less than satisfactory outcome postoperatively.<sup>10</sup> Aside from residual refractive error or overcorrection, these patients frequently have some form of irregular astigmatism induced by small optical zones and/or decentered ablations. These types of refractive errors are difficult to correct with standard treatments because of their irregular nature and would benefit many from customized ablation.

Although the term "customized treatment" usually is used for wavefront-guided treatments, topography-guided ablation is also a form of customized ablation. However, instead of conforming treatment to the wavefront map, it uses the patient's topography height map as the basis for the treatment.<sup>11</sup>

We previously reported our experience in enhancing these cases with wavefront-guided treatments with the ALLEGRETTO WAVE platform (WaveLight Technologie AG, Erlangen, Germany) with satisfactory success.<sup>12</sup>

### PATIENTS AND METHODS

The study design is a non-comparative case series on 27 eyes (22 patients) that underwent topography-guided enhancement with the ALLEGRETTO WAVE platform (Table). No control group was used or gender matching was done. These were unoperated cases that were treated by a single surgeon (A.J.K.) in a refractive surgery center in Athens, Greece.

Patients with previous myopic or hyperopic laser surgery who were dissatisfied with their quality of vision and either had residual myopia, hyperopia, or mixed astigmatism were included in the study. The indications were: 1) small original

From the Laser Vision Center, Institute of Ophthalmology, Athens, Greece; the Department of Ophthalmology, Manhattan Eye, Ear and Throat Hospital, New York, NY; and the Department of Ophthalmology, New York University Medical School, New York, NY.

The author has no financial interest in the materials presented herein.

Presented in part at the Sixth International Congress on Wavefront Science and Optimized Refractive Corrections, February 11-14, 2003, Athens, Greece.

Correspondence: A. John Kanellopoulos, MD, LaserVision Eye Institute, Messouris 2 & Vasilissis Sotiras Ave, Ampelokipoi, 11527, Athens, Greece; Tel: 30 210 5472 777; Fax: 30 211 7472 789; E-mail: akovision@internet.gr

Journal of Refractive Surgery • Volume 21 • September/October 2005



# Hyperopia-standard treatment Kanellopoulos-JRS 2006

Initial topography guided Hyperopic and Hyperopic Astigmatism LASIK Experience with the WaveLight ALLEGRETTO WAVE excimer laser in 120 Consecutive Eyes ARVO 2006-JRS 2006

## LASIK for Hyperopia With the WaveLight Excimer Laser

A. John Kanellopoulos, MD, Joseph Perryman, MD, Lawrence C. Ho, MD

### ABSTRACT

**PURPOSE:** To evaluate the safety and efficacy of the ALLEGRETTO WAVE excimer laser system (Allegretto Wave Laser Technology, Inc., Fuzhou, Germany) in LASIK for hyperopia and hyperopic astigmatism.

**METHODS:** One hundred twenty consecutive ALLEGRETTO WAVE excimer laser systems were used to treat 120 eyes of 60 patients. Patients were selected to be treated if they had hyperopia of +0.50 D or greater and astigmatism of 0.00 D or less, a minimum spherical equivalent refractive error of +0.50 D, and a corneal thickness of at least 0.00 D. Patients were treated with the WaveLight excimer laser system (WaveLight, Inc., Fremont, Calif.). Postoperative refraction was measured at 1 week, 1 month, 3 months, 6 months, and 1 year. Postoperative visual acuity, best spectacle-corrected visual acuity (BSCVA), night vision, contrast sensitivity, and patient satisfaction were also measured.

**RESULTS:** One hundred twenty eyes (100%) were treated with the ALLEGRETTO WAVE excimer laser system. The mean preoperative spherical equivalent refractive error was +0.50 D of the refractive error. For the refractive error group and the high refractive error group, 74% and 71% of eyes, respectively, were within 0.25 D of the refractive error. No eyes had a loss of BSCVA, 4% increase in higher order aberrations was noted in 10 eyes, 10% increase in higher order aberrations was noted in 10 eyes, 10% increase in higher order aberrations was noted in 10 eyes, 10% increase in higher order aberrations was noted in 10 eyes.

**CONCLUSIONS:** Hyperopia and hyperopic astigmatism were treated with the ALLEGRETTO WAVE excimer laser system. The safety and efficacy of the ALLEGRETTO WAVE excimer laser system in the treatment of hyperopia and hyperopic astigmatism. J Refract Surg. 2006;22:200-205.

**F**ocusing eye lenses have enhanced the safety and efficacy of hyperopia and astigmatic corrections with LASIK over the past several years.<sup>1-6</sup> In this study, we evaluated the safety and efficacy of the ALLEGRETTO WAVE excimer laser system (WaveLight Laser Technology AG, Erlangen, Germany) and the Moria M2 microkeratome (Moria, Inc., Antony, France) in our LASIK clinical practice for hyperopia with or without astigmatism. Subsequent to our study, the WaveLight technology gained Food and Drug Administration (FDA) approval in the United States for use in hyperopic and hyperopic astigmatism.<sup>7</sup>

### MATERIALS AND METHODS

One hundred twenty consecutive eyes of 60 patients underwent LASIK for hyperopia, hyperopic astigmatism, and astigmatism with hyperopia up to +0.75 diopters (D) and astigmatism up to 0.00 D, with a minimum spherical equivalent refraction of +0.00 D. Patients aged 18 years and above with a history of corneal surgery, hereditary eye disease, ocular dystrophy, current or past contact lens use, severe dry eye, and collagen vascular disease were excluded from this study.

Preoperative evaluation included uncorrected visual acuity (UCVA), refraction (manifest and cycloplegic), best spectacle-corrected visual acuity (BSCVA), slit-lamp examination, fundus examination, contact topography with the Orbscan T (Bausch & Lomb, Rochester, NY) and the ALLEGRETTO WAVE

From the Department of Ophthalmology, Massachusetts Eye, Ear, and Throat Hospital, Boston, Mass; (Dr. Kanellopoulos); and the Department of Ophthalmology, New York University Medical School, New York, NY (Dr. Perryman, Dr. Ho).

Presented in part as a poster at the Symposium for Research in Vision and Ophthalmology Annual Meeting, April 1-5, 2006, Orlando, Fla.

Presented in part as a poster for the European Society of Contact and Refractive Surgery Annual Meeting, September 1-5, 2006, Madrid, Spain.

The authors have no financial interests in the treatment discussed herein.

Correspondence: A. John Kanellopoulos, MD, Laser Vision Institute, 1000 Massachusetts Avenue, Suite 1000, Cambridge, Mass 02139, USA (e-mail: kanel@lvi.com).



Received June 4, 2005

Accepted March 21, 2006

# Is Angle kappa significant in hyperopes?





- **Measurement of angle kappa with synoptophore and Orbscan II in a normal population**
- Hikmet Basmak, MD<sup>1</sup>; Afsun Sahin, MD<sup>2</sup>; Nilgun Yildirim, MD<sup>3</sup>; Thanos D. Papakostas, MD<sup>4,5</sup>; and A. John Kanellopoulos, MD<sup>4,5</sup> 2007 J Refract Surg-in
- There is a significant correlation between positive refractive errors and large positive angle kappa values. Refractive surgeons must take into account angle kappa especially in hyperopic patients in order to avoid complications related to decent ration of ablation zone.

# Angle kappa adjustment topo-link




These figures depict the same planned excimer profile for the correction of hyperopic astigmatism on the left: centered on the pupillary center and on the right :adjusted by topography to take into consideration and adjust for angle kappa

# LASIK flap needs to be de-centered as well to accommodate Challenging for surgeon, Intralase?



# Treatment axis is centered on the visual axis and not pupil center







WAVELIGHT - ALLEGRO OCULYZER

Name: Diaggelakis, Christos ID: Date of Birth: 01.01.1958

Exam A: 05.04.2007 02:29:04 Right (25)		Exam B: 05.04.2007 02:28:01 Left (25)	
<p><b>Cornea Front</b></p> <p>Rh: 7.43mm K1: 45.4D Rv: 7.41mm K2: 45.6D Rm: 7.42mm Km: 45.5D</p> <p>QS: Blink! Axis: 168.0° Astig: -0.2D ecc: (7mm) 0.92 Rper: 8.17mm Rmin: 7.33mm</p>	<p><b>Sagittal Curvature (Front)</b></p>	<p><b>Cornea Front</b></p> <p>Rh: 7.03mm K1: 48.0D Rv: 6.97mm K2: 48.4D Rm: 7.00mm Km: 48.2D</p> <p>QS: OK Axis: 40.7° Astig: -0.4D ecc: (7mm) 1.29 Rper: 8.42mm Rmin: 6.60mm</p>	<p><b>Sagittal Curvature (Front)</b></p>
<p><b>Cornea Back</b></p> <p>Rh: 6.55mm K1: -6.1D Rv: 6.23mm K2: -6.4D Rm: 6.39mm Km: -6.3D</p> <p>QS: Blink! Axis: 10.0° Astig: +0.3D ecc: (7mm) 0.61 Rper: 6.81mm Rmin: 6.16mm</p>	<p><b>Elevation (Back) BFS=6.61 Float</b></p>	<p><b>Cornea Back</b></p> <p>Rh: 6.55mm K1: -6.1D Rv: 6.33mm K2: -6.3D Rm: 6.44mm Km: -6.2D</p> <p>QS: OK Axis: 178.3° Astig: +0.2D ecc: (7mm) 0.49 Rper: 6.75mm Rmin: 6.14mm</p>	<p><b>Elevation (Back) BFS=6.49 Float</b></p>
<p><b>Pachy:</b> x[mm] y[mm]</p> <p>Pupil Center: 544µm + -0.22 +0.20 Pachy Apex: 545µm 0.00 0.00 Thinnest Locat: 536µm -1.08 -0.58</p> <p>Cornea Volume: 57.6mm² KPD: +1.0D Chamb. Volume: 140mm² Angle: 31.3° ACD (Int.): 2.71mm Pupil D: 2.81mm IOP(Sum): ±0.0 Lens T:</p>		<p><b>Pachy:</b> x[mm] y[mm]</p> <p>Pupil Center: 535µm + +0.04 -0.11 Pachy Apex: 537µm 0.00 0.00 Thinnest Locat: 518µm +0.72 -1.37</p> <p>Cornea Volume: 56.6mm² KPD: +0.4D Chamb. Volume: 147mm² Angle: 27.5° ACD (Int.): 2.79mm Pupil D: 2.88mm IOP(Sum): +0.6 Lens T:</p>	

Keratoconus post LASIK:  
UCVA 20/400, removal of INTACS and  
then UVA. Post-op to 20/80



## Post-LASIK Ectasia



Dear Editor:

I report a patient who had post-LASIK ectasia and was managed in a novel fashion, without keratoplasty.

A 29-year-old male underwent unioocular LASIK 38 months ago. Little detail was available from the patient and the surgeon. His original uncorrected visual acuity (UCVA) before LASIK was 20/80, and his spectacle-corrected visual acuity (BSCVA) was 20/20 with refraction of sphere being  $-2.00-1.75 \times 85$ . Initially after the LASIK procedure, the patient reported that vision was good. During the following months, vision in that eye deteriorated. The original LASIK surgeon diagnosed ectasia and recommended the placement of Intacs (Addition Technology, Des Plaines, IL). After Intacs placement, his vision did not improve, and the patient developed severe night vision halos.

The treating LASIK surgeon then recommended penetrating keratoplasty (PK) as the next step, and the patient came for a second opinion for PK. 11 months after the original LASIK procedure and 3 months after Intacs implantation. Corneal topography is shown in Figure 1 (available at <http://aaojournal.org>), the central corneal thickness was  $410 \mu\text{m}$ , and the endothelial cell count was  $2750 \text{ cells}/\text{mm}^2$  (Conan, Boston, MA). I discussed with the patient the following:

1. The poor long-term experience with Intacs in post-LASIK ectasia that I have reported.<sup>1</sup>
2. The benefits and risks of PK.
3. Combined ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking and biomechanical stabilization of the ectasia.

After informed consent was given, I removed the Intacs. Two weeks later, I treated the ectatic cornea with a single application of combined ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking at  $3 \text{ mW}/\text{cm}^2$  for 30 minutes (KeraCure, Priavision, Menlo Park, CA) combined with the use of 0.1% riboflavin ophthalmic solution in 20% dextran T-500.

The treatment was performed after 20% alcohol-assisted epithelial removal. The riboflavin solution was then applied for approximately 2 minutes to soak the stromal bed and protect the iris, crystalline lens, and retina from the ultraviolet A irradiation, and then 1 drop every 2 minutes for a total of 30 minutes. A bandage contact lens was placed onto the cornea for 5 days and the patient treated with topical ofloxacin 1% (Ocuflox, Allergan, Irvine, CA) and prednisolone acetate 1% (Predforte, Allergan) 4 times a day for 10 days.

At 3 months, his UCVA improved from 20/400 to 20/70 and his BSCVA from 20/200 to 20/40. Refraction changed from  $-4.50-4.50 \times 120$  to  $-4.00-3.50 \times 115$ , and corneal topography changed as seen in Figure 1. The stability of these parameters and the corneal topography between

months 1 and 3 of this treatment encouraged me to proceed with topography-guided photorefractive keratectomy (PRK) to reduce the irregular astigmatism and try to provide the patient with a visual acuity not requiring the use of spectacles or a soft contact lens.

The corneal thickness at that point of  $420 \mu\text{m}$  enabled a PRK of his full spectacle correction with a topography-guided customized ablation on top of the LASIK flap (T-CAT software, Wavelight excimer laser, Wavelight, Erlangen, Germany). At the first post-PRK month, UCVA was 20/20 and BSCVA 20/20, with a refraction of  $+0.50-0.50 \times 160$ . There was no corneal endothelium count change. It is now 24 months after the operation and the patient enjoys UCVA of 20/20, although there are some mild night vision problems. Postoperative corneal topography is shown on Figure 1.

The most frequent management for post-LASIK ectasia has been PK.<sup>2</sup> Previous reports of the use of combined ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking mention a slowing down of keratoconus.<sup>3</sup> We have reported the management of extreme cornea irregularity with topography-guided ablations.<sup>4</sup> This is the first report of management of post-LASIK ectasia with combined ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking followed by customized PRK for visual rehabilitation. The apparent corneal stabilization, along with the successful visual rehabilitation, suggests that this approach may have a wider application as an alternative to therapeutic PK.<sup>5</sup>

Larger comparative studies and longer follow-up are obviously necessary to validate the long-term efficacy of this combined ultraviolet radiation and riboflavin treatment followed by a surface excimer laser treatment. Nevertheless, the refractive and topographic stability for 2 years appears to validate this minimally invasive treatment of iatrogenic keratectasia and leads me to believe that it may have an even wider application in the near future.

A. JOHN KANELLOPOULOS, MD  
Athens, Greece

### References

1. Kanellopoulos AJ, Pe LH, Perry HD, Donnenfeld ED. Modified intracorneal ring segment implantations (INTACS) for the management of moderate to advanced keratoconus: efficacy and complications. *Cornea* 2006;25:29-33.
2. Binder PS. Ectasia after laser in situ keratomileusis. *J Cataract Refract Surg* 2003;29:2419-29.
3. Wollensak G, Spoerl E, Siller T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol* 2003;135:620-7.
4. Kanellopoulos AJ. Topography-guided custom retreatments in 27 symptomatic eyes. *J Refract Surg* 2005;21:S513-8.
5. Donnenfeld ED, Kanellopoulos AJ. Therapeutic keratoplasty. In: Krachmer JH, Mannis MJ, Holland EJ, eds. *Cornea*. Vol. 3. St. Louis: Mosby; 1997:1843-54.





Figure 1. Display of topographies. 1, Corneal topography of this case when first seen by the authors, with central cornea ectasia and midperiphery flattening as an effect of the Intacs that were present. At this point, best spectacle-corrected visual acuity (BSCVA) is 20/200. 2, Corneal topography 2 months after the removal of Intacs and 1 month after combined ultraviolet radiation and riboflavin treatment to achieve collagen cross-linking. The central steepening is still present, and the effect of the Intacs removal relative to the previous image is appreciated mostly at the midperiphery, which appears steeper now. At this point, BSCVA is 20/200. **Bottom center**, An estimated corneal topographic ablation pattern as a laser treatment plan of the topography-guided procedure. It is notable that this ablation pattern is highly irregular, with a deeper ablation plan just inferior to and right of the center, which matches, however, the central cornea irregularity in the previous topographies. 4, Corneal topography 6 months after topography-guided photorefractive keratectomy. The central cornea appears more regular and much flatter. At this point, BSCVA and UCVA are 20/20. **Bottom left**, Comparison map depicting the result of subtraction of corneal topography 4 (final result) from corneal topography 1 (state of the complication when we encountered it). Impressively, the difference resembles the topography-guided ablation pattern (bottom center), demonstrating effectively the specificity of this treatment in reducing the pathogenic cornea irregularity, which, we theorize, contributed to the drastic improvement in BSCVA.



# keratoconus

27 y/o left eye is treated and the right observed over 3 years



# Collagen Cross-Linking (CCL) With Sequential Topography-Guided PRK

## A Temporizing Alternative for Keratoconus to Penetrating Keratoplasty

A. John Kanellopoulos, MD\*†‡ and Perry S. Binder, MS, MD§

**Purpose:** To assess the effectiveness of ultraviolet A (UVA) irradiation-induced collagen cross-linking (CCL) on keratoconus (KC) progression.

**Methods:** A patient with bilateral, progressive KC underwent UVA irradiation (3 mW/cm<sup>2</sup> for 30 minutes) after topical 0.1% riboflavin drops over a deepithelialized cornea. Twelve months later, a topography-guided penetrating keratoplasty (PRK; wavelight 400 Hz Eye-Q excimer) was performed in 1 eye for a refractive error of  $-3.50 -4.00 \times 155$  by using an attempted treatment of  $-2.50 -3.00 \times 155$ . At all postoperative follow-up visits to 18 months, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), pachymetry, and topography were performed.

**Results:** In the treated left eye, the UCVA after the UVA CCL improved from 20/100 to 20/80, and the BSCVA improved from 20/50 to 20/40. Eighteen months after the topography-guided PRK, the UCVA was 20/20, and the BSCVA was 20/15, with a refractive error of Plano  $-0.50 \times 150$ . The cornea was clear, and the endothelial cell count remained unchanged. The untreated right mate eye continued to progress during the same period.

**Conclusions:** The significant clinical improvement and the apparent stability of more than a year after UVA CCL, and subsequent PRK compared with the untreated mate eye, seems to validate this treatment approach for KC. An adjusted nomogram may be considered in the ablation of cross-linked cornea tissue to avoid overcorrections.

**Key Words:** keratoconus, cornea ectasia, surgical management, collagen cross-linking, ultraviolet A, riboflavin, customized topography-guided cornea ablation, visual rehabilitation

(*Cornea* 2007;26:891-895)

Keratoconus is a bilateral, nonsymmetric, and noninflammatory progressive corneal degeneration. Its incidence has been thought to be 1 in 2000 in the general population,<sup>1</sup> but the increased number of eyes undergoing screening for laser refractive surgery suggests the prevalence may be higher. It can be diagnosed at puberty, with up to 20% of the eyes progressing to the extent that penetrating keratoplasty is indicated.<sup>2</sup> Although spectacles and contact lenses can provide useful vision in many cases, there are several surgical options for those cases that can no longer benefit from them: implantation of intracorneal ring segments (Intacs or Ferrera rings),<sup>3</sup> lamellar keratoplasty,<sup>4</sup> or penetrating keratoplasty.<sup>2</sup> Other ectatic corneal disorders such as Pellucid marginal degeneration<sup>5</sup> and post-LASIK ectasia<sup>6</sup> require similar treatment approaches. Although penetrating keratoplasty for ectatic corneal disorders is highly successful, many eyes require contact lenses to correct the unpredictable topographic changes that are associated with sutures and postsuture abnormal corneal shapes, and sometimes the contact lens is not successful.<sup>7</sup>

In recent years, basic laboratory studies and subsequent clinical studies have suggested that by increasing the collagen cross-linking (CCL) of the corneal stromal collagen, one is able to increase the stiffness (biomechanics?) of the cornea with attendant stabilization of the normally progressive corneal disorder.<sup>8-16</sup> We present a case of bilateral progressive keratoconus that underwent unilateral CCL followed by PRK with an excellent outcome.

### CASE REPORT

A 26-year-old male patient had been treated with gas-permeable contact lenses for 8 years before his presentation. Because of debilitating giant papillary conjunctivitis he was no longer able to wear the contact lens; spectacles were unable to provide functional


J Cornea  
August  
2007

Cumulative average data

	pac h	steep K	BSCVA	myopi a	cyl	ECC	com p
pre	448	51.5	0.5	2.5	4.5	2850	
12m Post op	397	46	0.7	1.5	2.5	2850	6 cases haze

myopia and cylinder change following UVA CCL

myopia pre    myopia post    Cylinder pre    cylinder post






A 24 y/o pilot

Pre: UCVA 20/200

-4.5 -1.50 X 180 20/30


2 months post: UCVA 20/20

-0.25 -0.75 X34



# 16 months after the CCL

## A partial custom PRK





# An argument against PK?

Pre: UCVA: CF

-10.50 -3.5 X170 20/50

Post: UCVA 20/400

-9 -1.50 X75 20/25 uses SCL -7D



# Custom partial PRK and CCL

0.1% riboflavin + 7mW/cm<sup>2</sup> X 15minutes

**LaserVision.gr**  
WAVELIGHT - ALLEGRO OCULYZER

**Dr. A.J. Kanellopoulos, MD**  
Associate Professor, NYU Medical School

Name: [Redacted] ID: [Redacted] Date of Birth: 18.09.1984

Exam A: 90° K2: 44.9 D Astig: +3.2 D  
K1: 41.7 D ecc: (7mm) 0.37  
Axis: 121.9° QS: OK

Pachys: [Redacted] [Redacted] [Redacted]  
Pupil Center: + 556 μm -0.35 -0.09  
Thinnest Locat.: 513 μm -1.22 -1.42  
Chamber Volume: 208 mm<sup>3</sup> Angle: 33.0°  
A. C. Depth (Inl.): 3.38 mm Pupil Dia: 3.22 mm  
IDP(corr): [Redacted] Lens Th: [Redacted]

Sagittal Curvature (Front)

Exam B: 05.11.2007 12:39:09 Right (25) 90° K2: 40.4 D Astig: +1.5 D  
K1: 38.9 D ecc: (7mm) -0.18  
Axis: 121.8° QS: Model I

Pachys: [Redacted] [Redacted] [Redacted]  
Pupil Center: + 343 μm -0.09 +0.28  
Thinnest Locat.: 307 μm +0.88 +0.75  
Chamber Volume: 212 mm<sup>3</sup> Angle: 39.0°  
A. C. Depth (Inl.): 3.43 mm Pupil Dia: 3.25 mm  
IDP(corr): [Redacted] Lens Th: [Redacted]

Sagittal Curvature (Front)

Difference A - B 90° K2: +4.5 D Astig: +1.8 D  
K1: +2.7 D ecc: (7mm) +0.55  
Axis: +0.1° QS: [Redacted]

Pachys: [Redacted] [Redacted] [Redacted]  
Pupil Center: + +213 μm -0.26 -0.38  
Thinnest Locat.: 206 μm -2.10 -2.17  
Chamber Volume: -2 mm<sup>3</sup> Angle: -6.0°  
A. C. Depth (Inl.): -0.05 mm Pupil Dia: -0.04 mm  
IDP(corr): [Redacted] Lens Th: [Redacted]

Sagittal Curvature (Front)

Treatment type: **Topo-guided** Nomogram: S 101

Clinical: Sph: -2.66 D Cyl: -1.33 D Axis: 103° VD: 0.0 mm  
Topo: Sph: -1.24 D Cyl: -0.89 D Axis: 94°  
Modified: Sph: -2.75 D Cyl: -2.00 D Axis: 103° **Reset**

Tilt off

Ablation Depth: **dyn.** Zernike / RMS

Optical zone: 7.00 mm  
Transition zone: 1.00 mm  
Flap thickness: 0 μm  
Corneal thickness: 513 μm  
Stroma: 406 μm

Warnings and Messages:  
**Tilt was switched off manually!**

max: 106.93 μm cen: 100.86 μm act: 4.5

2D  Grid 3D ani

**Back** **Next**

# Conclusions

- Today's highly customized ablation tools offer visual rehabilitation in a broad range of corneas: regular to highly irregular.
- In our experience the Alcon/Wavelight topography guided platform has been very effective in predictably offering cornea normalization and enhanced visual function